logo
  

Nielsen Holdings Offers To Buy Harris Interactive For $2 A Share

Market research company Harris Interactive Inc. (HPOL), Monday said it has agreed to be bought by Nielsen Holdings N.V. (NLSN), a tracker of U.S. television ratings, for $2.00 a share.

Under the terms of the deal, Nielsen will start an offer to buy shares of Harris Interactive's common stock through a wholly owned subsidiary formed for the purpose of making the offer. Shareholders of Harris Interactive's will get $2.00 a share in cash.

The $2.00 per share offer represents a 2 percent premium to the average price in the 60 consecutive trading days prior to announcement of the transaction.

The Harris Interactive board of directors has unanimously approved the deal and certain of the directors of Harris Interactive have entered into tender and support agreements, representing approximately 12 percent of shares.

"This announcement reflects the successful completion of the turnaround strategy that we began in July 2011 and will deliver to Harris Interactive stockholders meaningful value and liquidity immediately upon closing," said Al Angrisani, President and Chief Executive Officer of Harris Interactive.

HPOL is currently trading at $2.04, down $0.04 or 1.92%, on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT